CRSP logo

CRSPCRISPR Therapeutics AG

$52.18
$0.10
(0.19%)
Overnight
Updated: 10:32 PM EDT·Prev Close $52.08
EarningsAug 10
Mkt Cap$5.02B
Vol1.27M
News
all
press releases
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential
Key PointsCRISPR's Casgevy cements the company as a leader in gene-editing therapies...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out
Key PointsEli Lilly just posted encouraging results from a clinical trial for a gene-editing candidate...
Nasdaq News: Markets
News Placeholder
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
Zacks
News Placeholder
Vertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious?
VRTX stock falls 7.9% in three months as Journavx and Casgevy sales missed expectations, but CF growth, Alyftrek momentum and renal pipeline progress stand out.
Zacks
News Placeholder
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks
News Placeholder
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026...
Yahoo! Finance: News
News Placeholder
The Biotech Supercycle Is Here: Retatrutide, VERVE-102, NEO100, and More Set to Transform Medicine
Biotechnology investors are entering one of the most catalyst-heavy clinical cycles in years as a wave of Phase 2 and Phase 3 programs begins reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders. $LLY, $NVO, $NTHI, $BAC, $STT, $BCS, $IMVT, $SRPT, $MRNA, $CRSP
24-7 Market News
News Placeholder
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?
Key PointsCRISPR Therapeutics has an approved product and several gene editing medicines in development...
Nasdaq News: Markets
News Placeholder
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
Zacks
<
1
2
...
>